缬沙坦在乳腺癌合并2型糖尿病患者应用曲妥珠单抗中的保护作用

Cardiac Protective Effect of Valsartan in Breast Cancer Patients with Type 2 Diabetes Receiving Herceptin Therapy

[目的]评价缬沙坦对合并2型糖尿病的乳腺癌患者应用曲妥珠单抗时对心脏的保护作用。[方法]将100例合并2型糖尿病的乳腺癌患者随机分为对照组和治疗组,每组50例,两组均应用曲妥珠单抗治疗,治疗组在用药前加用缬沙坦80mg每日1次口服,对照组加用同等剂量安慰剂。于用药前、用药后4周、12周、24周查心脏超声及血B型利钠肽(B-type natriuretic peptide,BNP)水平。[结果]对照组BNP较治疗组升高明显(P<0.05)。左室收缩末径、左室舒张末径较治疗组增加(P<0.05);射血分数较治疗组下降(P<0.05)。[结论]合并2型糖尿病的乳腺癌患者应用曲妥珠单抗时加用缬沙坦可保护心脏功能。

[Objective]To evaluate the cardiac protection effect of valsartan in breast cancer patients with type 2 diabetes mellitus(T2DM)receiving herceptin therapy.[Methods]One hundred breast cancer patients with T2DM were randomly divided into control group and trial group with50 patients in each group.Patients in both groups received herceptin therapy.Patients in trial group took valsartan 80 mg q.d before herceptin,while patients in control group were given the same dose of placebo.Echocardiographic examination was performed and plasma B type natriuretic peptide(BNP)levels were measured before and 4,12,24 weeks after treatment.[Results]The plasma BNP level in control group was higher than that in trial group.The left ventricular endsystolic dimension,left ventricular end-diastolic dimension were higher;and the ejection fraction in control group was lower than those in trial group(P<0.05).[Conclusion]Valsartan can protect heart function in breast cancer patients with T2DM who receive herceptin therapy.